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OBJECTIVES Enterococcus species are the fourth leading cause of bacteremia. Resistance rates are rising
and delays in appropriate initial antimicrobial therapy have been associated with increased mortal-
ity. Empiric treatment of patients with suspected enterococcal bacteremia varies and significant cost
differences exist between alternatives. The objective of this study was to determine the cost-effec-
tiveness of various empiric treatments for patients with suspected enterococcal bacteremia.
METHODS A decision-analytic model was constructed from the hospital perspective to assess the cost-
effectiveness of alternative empiric treatment options for enterococcal bacteremia, including antimi-
crobials active against vancomycin-resistant enterococcus (VRE). The model was populated from
available literature sources and included resistance patterns, associated mortality with early versus
delayed effective treatment, and the cost of treatment. Univariate sensitivity analyses tested the robust-
ness of the model to determine the degree to which model uncertainties influenced outcomes. We also
undertook a probabilistic sensitivity analysis varying parameters in 10,000 Monte Carlo simulations.
MAIN RESULTS The incremental cost-effectiveness ratio was $791 and $749/quality-adjusted-life-year
utilizing empiric daptomycin and linezolid, respectively. The model also predicted an incremental
cost/life saved of $11,703 by utilizing empiric daptomycin and $11,084 with linezolid utilization.
Ampicillin was dominated (i.e., less effective and associated with increased costs) by both VRE-
active agents and vancomycin. A probabilistic Monte Carlo sensitivity analysis showed that an agent
with VRE activity had a 100% chance of being cost-effective at traditionally used willingness-to-pay
thresholds. The decision-analytic model was sensitive to variations in E. faecium mortality and
short-term postdischarge survival rates.
CONCLUSION Results of our model showed that empiric utilization of an antimicrobial with activity
against VRE may be a cost-effective option for the treatment of suspected enterococcal bacteremia
when compared with vancomycin or b-lactam therapy.
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O R I G I N A L R E S E A R C H A R T I C L E S
Bloodstream infections represent nearly one-
third of hospital-acquired infections and are asso-
ciated with significant morbidity and mortality.1
Approximately 10% of bloodstream infections are
due to enterococcus species, making enterococcal
bacteremia the fourth leading cause of blood-
stream infection in North America.2 Commonly
used empiric treatment strategies include ampi-
cillin or vancomycin, but the prevalence of
vancomycin-resistant enterococcal (VRE) species
is on the rise with approximately 15–30% of
bloodstream isolates in North America demon-
strating resistance.3, 4 In particular, vancomycin
resistance in E. faecium species has become a
significant problem with resistance rates increas-
ing from 40% in 1997 to 61% in 2002.3 Further-
more, the majority of enterococcal strains that
are resistant to vancomycin are also resistant to
ampicillin, resulting in an increased role for anti-
microbials with activity against VRE (i.e., dapto-
mycin or linezolid) in the treatment of
enterococcal infections.5 These antimicrobial
resistance patterns are particularly concerning
because vancomycin resistance has been shown
to increase the risk of clinical failure, prolong
the length of hospitalization, and predict
mortality.4, 6–9 Bloodstream infections caused by
VRE are also associated with higher median hos-
pital costs when compared with vancomycin-sen-
sitive enterococcal bacteremias (VSE, $42,106 vs
$20,895).10
Research has demonstrated that early initia-
tion of appropriate antimicrobial therapy has the
potential to improve survival in patients with
enterococcal bacteremia. One study found that
receipt of effective antimicrobial treatment
within 48 hours significantly improved survival
at 14 days (odds ratio 0.21, p=0.02) in patients
with enterococcal bacteremia.4 These results
were supported by a retrospective analysis dem-
onstrating that in patients with positive entero-
coccal blood cultures, mortality was significantly
decreased when effective antimicrobial therapy
was started early (defined as on or before the
day of a positive culture result; odds ratio 0.39,
confidence interval 0.19–0.78).11 Another group
utilized peptide nucleic acid fluorescent in situ
hybridization (PNA FISH) technology to identify
bacteria approximately 2–3 days earlier than tra-
ditional culture methods.12 They confirmed that
patients with E. faecium bloodstream infections
received inadequate empiric antimicrobial ther-
apy 82–87% of the time, and that initiation of
effective antibiotics 2 days earlier significantly
decreased mortality from 45% to 26% (p=0.04).
With traditional culture methods, it may take up
to 2–3 days to identify E. faecium and begin an-
tiVRE antimicrobial therapy. These studies sug-
gest that if patients receive an effective
antimicrobial even 48 hours earlier, the potential
exists to significantly improve survival. However,
the cost associated with a course of each antibi-
otic is not equivalent, and VRE-active antibiotics
are currently associated with a significantly
higher daily cost than comparable drugs.13 The
increased morbidity, mortality, and costs associ-
ated with VRE bloodstream infections and the
clinical benefit of timely therapy make early,
effective treatment an important consideration.
International guidelines for the diagnosis and
management of intravascular catheter–related
infections provide recommendations about how
to initially manage patients with suspected bac-
teremias.14 Vancomycin is the recommended
empiric therapy in health care settings that have
an elevated prevalence of methicillin-resistant
Staphylococcus aureus. Linezolid should not be
used empirically unless institutions have a pre-
ponderance of methicillin-resistant Staphylococ-
cus aureus with vancomycin minimum inhibitory
concentration values above 2 lg/ml. Once en-
terococcal bacteremias are identified and suscep-
tibilities return, the recommended therapies are:
ampicillin for ampicillin-susceptible enterococci,
vancomycin if the pathogen is resistant to ampi-
cillin, and linezolid or daptomycin if both ampi-
cillin and vancomycin resistance are present. In
cases where VRE is the offending organism,
these recommendations assume susceptibilities
are known before therapy is changed, which
may lead to a delay in effective therapy if the
offending organism is resistant to initial therapy.
Given the high risk of mortality and cost differ-
ence between alternatives, we undertook an
analysis to determine the cost-effectiveness of
various empiric treatment strategies in patients
with suspected enterococcal bacteremia.
Methods
A decision-analytic model (DATA, TreeAge
Software Inc., Williamstown, MA) was con-
structed from the hospital perspective to assess
the cost-effectiveness of alternative empiric treat-
ment options for suspected enterococcal bactere-
mia in a hypothetical cohort of adult patients in
the United States. The base case outcome mea-
sures were defined as cost/life saved and as cost/
quality-adjusted life year (QALY). Incremental
cost-effectiveness ratios were calculated with the
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following formula: (Cost Treatment Option A –
Cost Treatment Option B)/(Effectiveness Treat-
ment Option A – Effectiveness Treatment Option
B). Our analysis was exempt from investigational
review board review according to institutional
policy. Univariate sensitivity analyses tested the
robustness of the model to determine the degree
to which model uncertainties influenced out-
comes. We also undertook a probabilistic
sensitivity analysis varying parameters in 10,000
Monte Carlo simulations.
Our model design is displayed in Figure 1. Our
hypothetical patient population consisted of adult
patients without documented immune-mediated
hypersensitivity reactions to any class of study
drugs. Patients with positive Gram stains for
Gram-positive cocci in chains received either a
b-lactam, vancomycin, or an antimicrobial with
activity against VRE. Daptomycin and linezolid
were selected as the VRE-active agents tested. We
investigated the impact of varying daptomycin
dosing regimens in the sensitivity and secondary
analyses. Our base case assumed the availability
of microbiologic rapid diagnostic testing such as
matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) or PNA FISH, which
allowed for species identification and prompt
antimicrobial stewardship team or provider
response to tailor empiric therapy. Patients ulti-
mately determined to have streptococcal bactere-
mia were excluded during efficacy and mortality
analyses. We accounted for the presence of strep-
tococcal species during the empiric treatment
phase by assessing the cost of treating these
patients until species identification to each treat-
ment arm. The prevalence of streptococcus and
enterococcus species were varied in our sensitiv-
ity analyses according to published reports.2 With
a few exceptions, patients remained on initial
therapies until susceptibilities returned. Patients
started on ampicillin and vancomycin were subse-
quently changed to a VRE-active agent after iden-
tification of E. faecium. Similarly, patients started
on vancomycin or a VRE-active agent were
switched to ampicillin if E. faecalis was identified
through rapid diagnostic testing. We assumed all
patients were promptly changed to appropriate
therapy according to international recommenda-
tions after species identification and susceptibility
reporting.14 Variation in the promptness of ther-
apy changes and the availability of rapid diagnos-
tic technology were investigated in our sensitivity
analyses.
The model was populated from available liter-
ature sources and included antimicrobial resis-
tance reports, mortality rates associated with
early versus delayed effective antimicrobial ther-
apy, and associated costs of enterococcal bacter-
emia treatment (Table 1). The attributable
inpatient cost of enterococcal bacteremia treat-
ment was obtained from a previously published
analysis and adjusted for inflation to 2013 dol-
lars using the consumer price index.10, 15 We
excluded pharmacy costs and assessed the incre-
mental treatment cost to patients with either
VRE or VSE bacteremias. Although one study
has reported a nonsignificant increased length of
stay of 1 day after implementation of rapid diag-
Figure 1. Decision tree comparing empiric treatment strategies in patients with suspected enterococcal bacteremias.
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nostic testing despite reporting an improved
time to appropriate antimicrobial therapy,12 we
chose not to increase the anticipated length of
stay in the base case scenario when susceptible
empiric therapy was correctly chosen. We
instead chose to analyze the incremental cost of
both increased and decreased lengths of stay in
our sensitivity analyses by assigning an incre-
mental cost/day for increased or decreased stay
corresponding to identification as a VRE or VSE
infection.10 Indirect costs associated with drug
preparation, administration, and monitoring
were assumed to be fixed and not included in
our model.
Survival rates associated with early versus
delayed treatment were obtained from the pub-
Table 1. Decision-Analytic Model Variables
Variable
Base Case
Value Range Distribution
Parameters
Mean (SD)
Costs
Ampicillin 2000 mg q 6 hrsa,13 $27 $10–50 Normal 2.7
Vancomycin 1000 mg twice/daya,13 $8 $4–50 Normal 1
Daptomycin 420 mg/daya,13 $254 $100–1000 Normal 51
Linezolid 600 mg IV twice/daya,13 $241 N/A N/A N/A
Attributable cost (excluding pharmacy costs)10, 15
Vancomycin-resistant enterococcus $50,627 $40,502–60,752 Normal 5063
Vancomycin-susceptible enterococcus $25,827 $20,622–30,922 Normal 2583
Incremental hospital cost a,10, 15
Vancomycin-resistant enterococcus $3468 $2468–4468 Normal 347
Vancomycin-susceptible enterococcus $2583 $1583–3583 Normal 258
Increased length of stay if not susceptible (days)12 0 1–6 Normal 1
Days until species identified 2 1–5 Normal 1
Days until susceptibilities return 4 1–14 Normal 1
Years survival12, 17 27 0.1–50 Normal 2.7
Probabilities
Gram positive cocci in chains identified as
enterococcal species2
0.5 0.3–0.7 Beta
E. faecalis
Prevalence1 0.35 0.1–0.9 Beta 0.035
Ampicillin susceptible21 1 0.8–1 Beta 0.01
Vancomycin susceptible21 0.96 0.8–1 Beta 0.096
Daptomycin susceptible21 1 0.8–1 Beta 0.01
30-day mortality when organism susceptible
to empiric therapy12
0.1 0–0.2 Beta .01
30-day mortality when organism nonsusceptible
to empiric therapy12
0.13 0.03–0.23 Beta 0.013
E. faecium
Prevalence1 0.51 0.1–0.9 Beta 0.051
Ampicillin susceptible21 0.054 0–0.2 Beta 0.005
Vancomycin susceptible21 0.283 0.08–0.48 Beta 0.028
Daptomycin susceptible21 0.997 0.8–1 Beta 0.099
30-day mortality when organism susceptible
to empiric therapy12
0.26 0.06–0.46 Beta 0.026
30-day mortality when organism nonsusceptible
to empiric therapy12
0.45 0.25–0.65 Beta 0.045
Other enterococcal species
Prevalence1 0.14 0.4–0.24 Beta 0.014
Ampicillin susceptible22 0.86 0.66–1 Beta 0.086
Vancomycin susceptible22 0.86 0.66–1 Beta 0.086
Daptomycin susceptible22 1 0.8–1 Beta 0.01
30-day mortality when organism susceptible
to empiric therapy12
0.1 0–0.2 Beta 0.01
30-day mortality when organism nonsusceptible
to empiric therapy12
0.13 0.03–0.23 Beta 0.13
Utilities
QALY12 0.8 0.5–1 N/A
Discount rate 3% 0–6% N/A
aDaily cost.
SD = standard deviation; IV = intravenous; N/A = not applicable; QALY = quality-adjusted life year
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lished report discussed previously.12 Initiation of
effective empiric enterococcal treatment resulted
in improved survival in all enterococcal species
with the largest benefit observed in patients with
E. faecium. Survival differences were not
reported in patients with enterococcal species
other than faecalis and faecium. For enterococcal
species, we assumed a survival difference equiva-
lent to patients with E. faecalis and analyzed
potential variations in mortality rates in our sen-
sitivity analyses.
We utilized a QALY utility measure corre-
sponding to a study that reported a 20%
reduction in quality of life after a septic epi-
sode.16 Thus, we predicted an additional year of
survival would generate 0.8 QALYs. The median
age of patients with enterococcal bacteremia in
the earlier trial was 56 years. We therefore esti-
mated that survivors would live 27 additional
years after development of enterococcal bactere-
mia.17 All utilities and costs were valued in
2013 dollars (U.S.) and discounted at a rate of
3%.15
Results
The results of our analyses are listed in
Table 2. Using empiric vancomycin as the pri-
mary point of reference, the incremental cost-
effectiveness ratio utilizing empiric daptomycin
compared with alternatives was $791/QALY. Our
model predicted that 14 patients would need to
be treated with a VRE-active agent rather than
vancomycin to save one life. The incremental
cost/life saved associated with the empiric use of
daptomycin in these patients was $11,703. Utili-
zation of linezolid as the VRE-active agent
resulted in an incremental cost/QALY of $749
and an incremental cost/life saved of $11,084.
Ampicillin was dominated (i.e., less effective and
associated with increased costs) by both dapto-
mycin and vancomycin for cost/life saved and
cost/QALY.
A probabilistic Monte Carlo sensitivity analy-
sis showed that both VRE-active agents had a
100% chance of being cost-effective at a willing-
ness-to-pay threshold of $100,000/QALY and at
$50,000/QALY (Figure 2). Daptomycin had a
93% chance of being cost-effective at a cost/life
saved threshold of $50,000 and a 99.5% chance
at $100,000/life saved.
Both models proved robust to variations in
nearly all model parameters at a willingness-
to-pay threshold of $50,000. The models were
sensitive to changes in E. faecium mortality rates
and short-term postdischarge survival rates.
Vancomycin was more cost-effective if the long-
term survival was less than 4 months after devel-
opment of bacteremia. Empiric use of a VRE-
active agent was no longer cost-effective at our
willingness-to-pay threshold when mortality due
to delayed effective therapy in patients with
E. faecium dropped from 45% to 26.2% (cost/
QALY) or 30.4% (cost/life saved), while the mor-
tality rate associated with appropriate antibiotic
selection remained at 26%. Likewise, increasing
E. faecium mortality rates without delays in ther-
apy from 26% to 40.6% in the cost/life saved and
44.8% in our cost/QALY models, respectively,
negated the advantage for a VRE-active agent
when E. faeciummortality remained 45%. Varying
the mortality rates in patients with bacteremia
from other enterococcal species to reflect
mortality rates similar to E. faecium, rather than
Table 2. Cost-effectiveness of Empiric Enterococcal Bacteremia Treatment Strategiesa
Strategy Cost Incremental Cost Effect Incremental Effect Incremental C/E (ICER)
Base Case (Cost/life saved) (Survival %) (Survival %)
Vancomycin therapy $35,967 74.5
b-lactam therapy $36,030 $63 71.9 2.7 Dominated
VRE-active therapy
Daptomycin $36,775 $808 81.4 7 $11,703
Linezolid $36,719 $765 81.4 7 $11,084
Base Case (Cost/QALY) (QALY) (QALY)
Vancomycin therapy $35,967 11
b-lactam therapy $36,030 $63 10.6 0.4 Dominated
VRE-active therapy
Daptomycin $36,775 $808 12.1 1 $791
Linezolid $36,719 $765 12.1 1 $749
aCalculations for cost-effectiveness were performed by taking the incremental cost (difference between costs of compared strategies) divided
by the incremental effectiveness (difference between the effectiveness of the compared strategies).
C/E = cost/effectiveness; ICER = incremental cost-effectiveness ratio; VRE = vancomycin-resistant enterococci; QALY = quality-adjusted life
year
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E. faecalis, did not have an impact on the results.
No other variable within our predefined sensitiv-
ity ranges had the potential to impact the results
of the model. This included the QALY utility mea-
sure utilized, drug acquisition costs, susceptibility
reporting times, variations in length of stay, or
hospitalization cost.
Utilizing increased dosing regimens of dapto-
mycin had minimal impact on economic burden.
The incremental cost/QALY and incremental cost/
life saved by utilizing 8 mg/kg of daptomycin ver-
sus 6 mg/kg in a 70-kg patient was $1061 and
$15,747, respectively. Utilization of 10 mg/kg
daptomycin dosing in the same 70-kg patient pro-
vided similar results ($1334/QALY and $19,744/
life saved). We also investigated the impact of
increased doses in obese patients through a wide
range on VRE-active agent cost in our sensitivity
analyses. No variation in patient weight, up to
and including a 277-kg patient dosed at 6 mg/kg,
had the potential to impact results based on our
willingness-to-pay thresholds.
Empiric utilization of a VRE-active agent (i.e.,
daptomycin or linezolid) remained cost-effective
when we analyzed scenarios without the benefit
of rapid diagnostic testing technology or prompt
deescalation. When the initial treatment choice
was continued until susceptibilities returned, use
of daptomycin remained cost-effective ($1433/
QALY and $21,369/life saved). Likewise, empiric
utilization of daptomycin proved cost-effective
when rapid diagnostic testing was not present
and deescalation from daptomycin to vancomy-
cin when VSE was identified did not occur
($1788/QALY and $26,464/life saved).
Discussion
Results of our analysis demonstrate that
empiric utilization of an antimicrobial with
activity against VRE followed by prompt deesca-
lation once susceptibilities return is cost-effec-
tive in patients with suspected enterococcal
bacteremia. When compared with utilization of
vancomycin or a b-lactam antimicrobial, our
model predicted that effective empiric coverage
against VRE improves overall survival, as well as
patients’ quality of life, at a cost well below tra-
ditional willingness-to-pay thresholds.
Our analysis has several limitations that deci-
sion makers should consider before implement-
ing widespread empiric use of VRE-active agents
in this patient population. First, we did not
predict future consequences of increased VRE-
active agent utilization. Many institutions reserve
agents with VRE activity in order to extend the
effective life of these agents. Resistance and col-
lateral damage would likely be accelerated with
widespread use. Predicting the economic or clin-
ical consequences of future resistance patterns
would be difficult to quantify and beyond the
scope of this analysis. We hope further studies
shed more light on this going forward. The role
of antimicrobial conservation should remain an
important consideration for decision and policy
makers when developing treatment guidelines
and algorithms based on this evidence.
Another limitation is that we did not incorpo-
rate costs of adverse events associated with use
of either treatment regimen. The clinical and
financial impact of adverse reactions such as
nephrotoxicity, creatinine-kinase elevations, or
immune-mediated reactions would have affected
each arm differently. The short empiric therapy
timeframe of our analysis would lessen expo-
sure, which may decrease, though not eliminate,
incidence of adverse events and associated costs
between alternatives. In addition, we are una-
ware of studies reporting adverse event rates for
treatment alternatives during the time between
the beginning of empiric therapy and the return
of susceptibilities. Including accurate adverse
event estimates would therefore prove very diffi-
cult and beyond the scope of our analysis.
Integration of rapid diagnostic testing
(MALDI-TOF or PNA FISH) with antimicrobial
stewardship team intervention or provider ability
to tailor therapy on species identification may
not be a reality in most health systems at this
time. As mentioned previously, our base case
focused on the time from identification of
Figure 2. Incremental cost-effectiveness (ICE) scatterplot
comparing a vancomycin-resistant enterococcus (VRE)
active agent versus vancomycin across 10,000 simulations
at a willingness-to-pay threshold of $50,000 per quality
adjusted life year (QALY).
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species on Gram stain until susceptibilities were
reported and deescalation occurred. Assuming
availability of this technology in our base case
biased results against vancomycin or ampicillin
since there was less exposure to the costly VRE-
active agents. However, we accounted for
variations in time to species and susceptibility
identification in our sensitivity analyses by inves-
tigating results with and without the availability
of rapid diagnostic testing. Empiric utilization of
VRE-active agents remained cost effective in
institutions under both scenarios. Likewise, we
were also able to investigate whether deescala-
tion through good antimicrobial stewardship
practices was essential to maintain results. Our
model predicted that continuing a VRE-active
agent for a 2-week treatment course without
deescalation was also cost-effective. Although we
advocate for deescalation when appropriate and
caution that extending the treatment duration in
this secondary analysis compounds several of the
model’s preexisting limitations, these secondary
results provide further information for decision
makers without antimicrobial stewardship pro-
grams or mechanisms at their institution to
ensure consistent deescalation.
Patients with prolonged intensive care unit
admission, neutropenia, or liver transplantation
with VRE colonization may be at higher risk for
the development of VRE bacteremia based on
surveillance cultures or prior colonization.18–20
We did not analyze scenarios where empiric ini-
tial therapy could be guided by these risk factors.
However, the higher likelihood of developing a
VRE versus VSE bacteremia in these populations
would strengthen the efficacy projections and
further improve the cost-effectiveness of empiric
utilization of a VRE-active agent. Our model
predicted that even institutions with lower rates
of VRE or higher rates of E. faecalis would bene-
fit from empiric utilization of an agent with VRE
activity. Daptomycin remained the preferred
empiric antimicrobial at a willingness-to-pay
threshold of $50,000/QALY when the prevalence
of E. faecalis was set to an intentionally high
90%. When E. faecium isolates were analyzed
individually, a VRE-active agent was cost-effective
only when vancomycin susceptibility was greater
than 99%.
Finally, our model is based on published stud-
ies and microbiologic incidence and susceptibil-
ity reports. We were unable to incorporate very
recent national enterococcal species prevalence
or susceptibility estimates. Further, individual
institution or regional streptococcal and entero-
coccal prevalence and susceptibility data may
vary. We intentionally set wide sensitivity
ranges, and our univariate and probabilistic sen-
sitivity analyses confirm results across a range of
likely susceptibility and prevalence scenarios.
Similarly, although a number of studies have
demonstrated that early initiation of appropriate
antimicrobial therapy has the potential to
improve survival in patients with enterococcal
bacteremia, the efficacy data used in our analysis
were primarily pulled from one analysis.4, 11, 12
If we are to believe that early effective therapy
does not improve survival, then the cost of using
empiric VRE-active therapy to the institution
and society may be considerable. The estimated
increased cost by utilizing a VRE-active agent
until the organism strain is identified is approxi-
mately $800/patient. This cost could rise
depending on factors such as the dosing
regimens, patient-specific factors, and whether
VRE-active therapy is not promptly deescalated
once the organism is identified or susceptibilities
return. Depending on the incidence of suspected
enterococcal bacteremia, this additional cost
could drive up health care costs considerably,
which is a particular concern in today’s cost-
conscious health care environment. Results of
our analysis suggest that if there is even the
slightest mortality benefit from timely effective
antimicrobial selection, then selection of an agent
with activity against VRE combined with prompt
deescalation saves lives and improves patients’
quality of life at a minimal cost. As with all eco-
nomic modeling, real-world results are needed to
validate or refute results of our analysis.
To our knowledge, this is the first analysis
investigating the cost-effectiveness of empiric
antimicrobial selection in patients with sus-
pected enterococcal bacteremia. Our results
showed that empiric utilization of an antimicro-
bial with activity against VRE may be a cost-
effective option for the treatment of suspected
enterococcal bacteremia when compared with
vancomycin or ampicillin. Results of our analysis
provide prescribers, antimicrobial stewardship
teams, and other decision makers with addi-
tional information when considering empiric
antimicrobial therapy for the treatment of
patients with suspected enterococcal bacteremia.
Conclusion
Empiric utilization of an antimicrobial with
activity against VRE may be a cost-effective option
for the treatment of suspected enterococcal
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bacteremia when compared with vancomycin or a
b-lactam antimicrobial.
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